Anti-Mouse/Human CD273 (PD-L2) [Clone 3.2.B8] — Purified in vivo PLATINUM™ Functional Grade

Clone 3.2.B8 is a monoclonal antibody that targets PD-L2 (CD273) and is widely used in mice for in vivo immune checkpoint blockade studies, particularly to modulate T cell responses by inhibiting the PD-L2/PD-1 interaction.

Key in vivo applications include:

• Immune checkpoint blockade: The primary use is to disrupt the PD-L2/PD-1 signaling pathway in mice, which is critical for studying immune regulation, T cell activation, and tolerance. This is commonly applied in models of cancer immunotherapy and studies exploring the regulation of autoimmune responses.
• Functional blocking studies: Clone 3.2.B8 is employed to functionally block PD-L2 in living animals, thereby helping to investigate the biological role of PD-L2 in various physiological and disease contexts, such as infection, tumor immunity, and autoimmunity.
• Flow cytometry and cell depletion studies: While most commonly used for checkpoint blockade, the antibody has also been validated for in vivo flow cytometry-based depletion and modulation of cell populations expressing PD-L2.

Additional details:

• Cross-reactivity: Clone 3.2.B8 binds both mouse and human PD-L2, making it useful in some translational and humanized mouse studies.
• Preclinical immunology research: It is employed in models to investigate mechanisms regulating the immune environment, especially in experimental systems where modulation of the PD-1 pathway is of interest.

Overall, clone 3.2.B8 is a well-characterized in vivo tool for probing the function of PD-L2 in mouse models of immunity and immunotherapy.

Commonly used antibodies or proteins studied with clone 3.2.B8 (anti-mouse PD-L2/CD273) in the literature include:

• PD-1 (Programmed death-1)
• PD-L1 (Programmed death-ligand 1)
• CD3 (a pan-T cell marker)
• CD4 (helper T cell marker)
• CD8 (cytotoxic T cell marker)
• CD11c (dendritic cell marker)
• MHC-II (major histocompatibility complex class II, expressed on antigen-presenting cells)

These combinations are common in studies investigating immune checkpoint regulation, T cell activation, and immune cell phenotyping. They are especially prevalent in immuno-oncology and autoimmunity research contexts, as blocking the PD-1/PD-L2 axis often requires co-detection of these critical immune markers to fully characterize the cellular and functional effects of PD-L2 blockade.

In checkpoint inhibition research, anti-PD1 and anti-CTLA4 antibodies are also commonly used alongside 3.2.B8 to study synergistic or combinatorial therapeutic effects. However, 3.2.B8 is most often combined specifically with phenotyping and additional inhibitory/stimulatory checkpoint markers to map immune modulation in vivo and in vitro.

Clone 3.2.B8 is a monoclonal antibody widely cited in scientific literature as a highly specific tool for detecting PD-L2 (CD273) on both mouse and human cells.

Key findings from its citations include:

• Cross-Species Reactivity: Clone 3.2.B8 binds both mouse and human PD-L2 with high specificity, making it valuable in comparative immunology and translational research.

• Tool for Immune Checkpoint Research: The antibody is extensively used to study the PD-1/PD-L2 pathway, which negatively regulates immune responses. This supports investigations into how PD-L2 contributes to immune tolerance, clonal selection, and modulation of T cell responses in health and disease.

• Applications in Oncology and Autoimmunity: Clone 3.2.B8 enables robust characterization and targeting of the PD-1/PD-L2 axis in models of cancer and autoimmunity, including studies on the impact of checkpoint blockade therapies in preclinical settings. For example, papers cite its use in dissecting how PD-L2, versus PD-L1, influences immune reactions such as airway inflammation and tumor-infiltrating lymphocyte exhaustion.

• Lack of Direct Infectious Disease Data: No findings link clone 3.2.B8 directly to research on infectious diseases or TCR clonotype analysis in the context of HIV studies. Its impact is primarily in immune modulation and checkpoint biology.

• Experimental Validation: It is used in functional assays (e.g., flow cytometry, Western blots), and experimental protocols emphasize the need for optimization and validation to ensure efficacy and tolerability when used in vivo.

• Example Citations:

  • Akbari O, et al. (2010): Demonstrated PD-L2’s distinct modulatory roles in airway inflammation compared to PD-L1.

In summary, scientific literature cites clone 3.2.B8 as a critical reagent for mechanistic studies and therapeutic investigations involving PD-L2 in immune regulation, especially in mouse models of immunity and cancer, but not in infectious disease contexts.

Dosing Regimens of Clone 3.2.B8 in Mouse Models

No Standardized or Model-Specific Dosing for Clone 3.2.B8

The search results specifically highlight that there is no direct, detailed, or standardized dosing information for clone 3.2.B8 (anti-mouse CD273/PD-L2) in mouse models. The product listing and available scientific literature do not provide model-specific or disease-specific dosing regimens for this clone. This contrasts with other widely used antibodies (e.g., anti-CTLA-4, anti-NK1.1), for which standardized dose ranges and schedules are well-documented.

General Guidance and Recommendations

Adapting from Similar Antibodies

When direct data are unavailable, researchers are advised to adopt dosing regimens from antibodies targeting similar pathways (e.g., other checkpoint inhibitors like anti-PD-1 or anti-CTLA-4), and to adjust for the specific biology of the mouse model being used. For most immune checkpoint antibodies in mice, standard doses typically range from 5–300 μg per mouse, administered via intraperitoneal (i.p.) or intravenous (i.v.) injection.

Dosing for Related Immune Checkpoint Antibodies
As a reference, other checkpoint antibodies (such as anti-CTLA-4 clone 9H10 or 9D9) are commonly dosed at 100–250 μg per mouse, i.p., every 3 days. However, these are not directly transferable to clone 3.2.B8 without experimental validation.

Critical Steps for Protocol Development

• Preliminary Validation: Always perform initial experiments to determine the optimal dose, route, and schedule for clone 3.2.B8 in your specific mouse model.
• Tolerability and Efficacy: Monitor for tolerability (adverse effects) and efficacy (biological effect) to refine the regimen.
• Model-Specific Adjustments: Consider strain, age, sex, disease context, and endpoint when designing the regimen, as these can significantly affect antibody pharmacokinetics and pharmacodynamics.

Summary Table: Clone 3.2.B8 Dosing in Mouse Models

Conclusion

There is no established, model-specific dosing regimen for clone 3.2.B8 in mouse models. Researchers must base initial dosing on general guidelines for immune checkpoint antibodies, then empirically determine the optimal regimen for their specific experimental context through careful validation. Always consult recent literature and, if possible, contact the antibody provider or collaborating labs for unpublished data or recommendations.